Literature DB >> 8078379

Antibiotics for pneumonia therapy.

L A Mandell1.   

Abstract

When treating any infectious disease, a physician selects an antimicrobial based on the following considerations: the in vitro activity of the drug, its pharmacokinetic properties, the efficacy data based on properly designed and conducted clinical trials, and finally the adverse effects. In this article, all of these factors, with the exception of adverse effects, were discussed. It was neither my intent nor my purpose to deal with side effects or adverse drug reactions because these are well covered in standard texts or physician references such as the Physicians' Desk Reference and the American Hospital Formulary Service (United States) and the Compendium of Pharmaceuticals and Specialties (Canada).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8078379     DOI: 10.1016/s0025-7125(16)30116-x

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  4 in total

1.  Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 3.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 4.  Azithromycin for acute lower respiratory tract infections.

Authors:  Malinee Laopaiboon; Ratana Panpanich; Kyaw Swa Mya
Journal:  Cochrane Database Syst Rev       Date:  2015-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.